Improving the Clinical Evidence of Bone Graft Substitute Technology in Lumbar Spine Surgery

Wellington K. Hsu1 M. S. Nickoli1 J. C. Wang2 J. R. Lieberman3 H. S. An4 S. T. Yoon5 J. A. Youssef6 D. S. Brodke7 C. M. McCullough8

1 Department of Orthopaedic Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
2 Department of Orthopaedic Surgery, UCLA Comprehensive Spine Center, Santa Monica, California
3 University of Connecticut Medical Center, Farmington, Connecticut
4 Rush University Medical Center, Chicago, Illinois
5 Emory Spine Center, Atlanta, Georgia
6 Durango Orthopedic Associates, PC/Spine Colorado
7 University of Utah, Salt Lake City, Utah
8 Resources for Medical Education and Collaboration, Durango, Colorado

Global Spine J 2012;2:239–248.

Abstract

Bone graft substitutes have been used routinely for spine fusion for decades, yet clinical evidence establishing comparative data remains sparse. With recent scrutiny paid to the outcomes, complications, and costs associated with osteobiologics, a need to improve available data guiding efficacious use exists. We review the currently available clinical literature, studying the outcomes of various biologics in posterolateral lumbar spine fusion, and establish the need for a multicenter, independent osteobiologics registry.

Keywords
► bone graft substitute
► spine fusion
► biologics
► osteobiologics
► demineralized bone matrix
► ceramics
► bone morphogenetic protein
► autograft

Lumbar spine fusions are performed at a rate of 250,000 per year in the United States alone,1 and in each case, surgeons are faced with the critical decisions regarding choice of bone graft. In an arena that once demonstrated near-exclusive use of iliac crest bone graft in 1990s, surgeons are now split between the use of growth factors, allograft, demineralized bone matrix (DBM), and ceramics, to name just a few. Despite this transformation to the use of bone graft substitutes to avoid the complications associated with autograft harvest, the comparative and high-quality evidence that researchers and practitioners must rely on is sparse. Although bone regenerative technology research has been conducted for over 4 decades, there has yet to be established an accepted, cost-effective, and efficacious algorithm for patients undergoing lumbar spinal fusion.

Outcomes from the use of bone graft substitutes in bone healing are almost nonexistent except for a few commercially available products. The chief reason for this is the expense involved in designing and implementing clinical studies. Though select osteobiologics have been studied in detail, such as bone morphogenetic protein, the resources to obtain similar evidence for other products are often unavailable. Furthermore, even the available data vary substantially in quality, design, outcome measures, and consequently,
conclusions. Finally, many products are regulated as “minimally manipulated human allograft” by the Food and Drug Administration (FDA), which does not require a randomized controlled trial or premarket approval for clinical use. Because a large amount data outside of the peer-reviewed literature are often pushed as industry-driven marketing tools, surgeons must actively seek high-quality evidence to make appropriate choices for patient care. Due to the large number of osteobiologics on the market, there exists a need for a focused study group to collect, analyze, and report data.

To that end, complications have been reported from the off-label and misuse of bone graft substitutes. Because products are commonly used off-label without formal data, invariably, there is an incomplete understanding of mechanism, tissue response, and proper application before patients are exposed. The most recent fallout of the clinical studies involving bone morphogenetic protein has led to increased scrutiny of data presentation, potential conflicts of interest, and patient safety. As it stands now, the void of an independent organization to study outcomes, costs, and technique makes it difficult to navigate through mere allegations and true fact.

This article will review the clinical evidence on bone graft substitutes in lumbar posterolateral spine fusion and present the need for a collaborative effort to improve the available data.

**Study Design**

Medline, Embase, and Cochrane Central Register of Controlled Trials through July 2010 were searched for publications from 1980 to 2011 with a combination of the keyword “spine fusion” and one other of the following: “bone graft substitute,” “allograft,” “ceramic,” “deproteinized bone matrix,” “autograft,” “local bone,” “bone marrow aspirate,” “growth factor,” “bone morphogenetic protein,” and “stem cells.” Query results were reviewed by two independent observers, and articles for inclusion of this study were selected using the following criteria:

- Clinical studies, level of evidence grade I to IV and agreed upon according to *Journal of Bone and Joint Surgery (American Edition)* guidelines by two independent reviewers
- Sample size of >10 patients
- Instrumented posterolateral lumbar fusion only (one- to three-level; no interbody)
- Minimum of 1-year radiographic follow-up
- Diagnosis of a degenerative condition of the lumbar spine (spondylolisthesis, degenerative disc disease)
- Adult patients with a minimum age of 18 years old
- Reported fusion rates

Fusion rate was defined by plain radiographs and/or computed tomography (CT) imaging depending on the method reported in the respective study. Approximately 80% of the publications utilized plain radiographs with anteroposterior/lateral/extension views as the primary means to evaluate bone fusion. CT scan was often used in cases of disagreement between reviewers for each publication, as determined by the respective authors. CT scan has been historically more stringent in the assessment of solid bony fusion and generally has led to lower fusion rates than that assessed with plain radiographs. However, because of recent concerns with cancer risk from the radiation exposure from CT technology, more recent clinical studies have focused on the use of routine plain radiographs to assess bony growth. For the purposes of this article, because studies that utilized CT scan were far fewer than plain radiographs and included each biologic, all radiographic data were compiled together.

For studies utilizing more than one type of bone graft substitute, groups were categorized in accordance with the authors’ original objective and hypothesis. For example, if the authors’ intent was to study the efficacy of a ceramic, then ceramic/local autograft or ceramic/BMA was placed in the ceramic group. Studies involving bone marrow aspirate (BMA) that was processed and concentrated were classified into a BMA group, whereas nonconcentrated BMA groups were categorized into those of the accompanying bone graft substitute. In the bone morphogenetic protein group, only those studies utilizing FDA-approved products for routine use (rhBMP-2 and the product INFUSE™) were included.

**Results**

A total of 38 studies met the inclusion criteria. Of these studies, four provided data on allograft alone,1–7 two on concentrated BMA,8,9 16 on ceramics,10–25 three on DBMs,26–28 eight on local autograft alone,17,29–34 three with recombinant bone morphogenetic protein-2 (rhBMP-2; INFUSE™)35–37 and four on autologous growth factors14,25,38,39 (>Table 1). Articles were subsequently classified based on level of evidence: 8 level I, 10 level II, 8 level III, 12 level IV (>Table 2). A group with the use of autologous iliac crest bone graft was performed in 23 of these studies (as a respective control group), and the collective fusion rate calculated.

**Iliac Crest Bone Graft**

Iliac crest bone graft was harvested in a control group in 23 studies in a total of 1389 patients. A total of 79% (range 40 to 100%) were deemed to be successfully fused by the respective authors. Surgical technique, volume, and patient population varied with each study; however, in many studies, the details regarding graft harvest were not included. These data are consistent with historical data that report fusion rates with the use of iliac crest bone graft in posterolateral lumbar fusion from 50 to 90%.29,40

**Local Bone Graft**

Although some studies have reported unacceptable fusion rates in clinical trials in the past,40,41 the use of local bone graft from laminectomy and facetectomy sites where decompression has grown in popularity in recent years. Improvements in technique of local bone preparation, such as soft tissue dissection, morselization, and bone preservation, have led to many surgeons’ use in the lumbar spine. In vitro data have suggested that osteoblast content is greater in cancellous...
bone from laminar bone than iliac crest.\textsuperscript{42} The one significant disadvantage in the use of local bone graft is the limited supply that depends upon the spinal levels decompressed. In eight studies with a total of 714 patients with local bone graft alone (without bone marrow aspirate), a total of 89\% (range 65 to 95\%) successfully fused based upon plain radiographic imaging.

**Allograft**

Allograft, or processed cadaveric bone, confers advantages over autogenous bone graft in an abundant supply of material and the avoidance of complications associated with graft harvest. Preserved through either frozen or freeze-dried processes, antigenicity is reduced, leading to increased graft incorporation. Although the risk of disease transmission exists with the use of allograft, standards in screening donor tissue have reduced the risk of HIV disease transmission to no greater than 1 in 1.5 million.\textsuperscript{43} Because allograft-based products are classified as minimally manipulated human cellular tissue products by the FDA, little data are required for a product to reach the marketplace. Allografts are thought to only offer osteoconductive activity.

A total of 269 patients treated with allograft alone in a posterolateral lumbar fusion in four studies were identified. Formulations were described as chips, powder, and "matchsticks." A collective fusion rate of 52\% was calculated (range 0 to 92\%).

### Demineralized Bone Matrix

DBM is derived from the acid extraction of the mineralized phase of allograft bone. Allogeneic bone is crushed to a particle size of 74 to 420 μm, followed by demineralization in 0.5 N HCl mEq/g for 3 hours.\textsuperscript{44} In vitro studies have demonstrated osteoinductivity with survival retention of growth factors after this process. However, there is wide variability in the way DBMs are processed including sterilization methods, associated carrier, and percent of human tissue present. Commercial preparations include a variety of associated substances such as glycerol, hyaluronic acid, gelatin, and calcium sulfate powder.\textsuperscript{45,46}

Preclinical studies have demonstrated a wide variability in the performance of various DBMs in the formation of bone and osteogenic gene expression.\textsuperscript{45-47} Much of this inconsistency can be attributed to the different ways that DBM is constructed. Furthermore, the quality of donor tissue is also thought to be directly related to in vivo performance. Finally, translational studies have repeatedly demonstrated the wide variability in this osteoinductivity not only among different products, but also with different lots of the same product.\textsuperscript{48}

Despite the fact that over 50 DBM products are commercially available for use in the lumbar spine, only three clinical studies in 192 patients report its use in the posterolateral lumbar spine. In each of these studies, DBM was used as an extender to local bone graft. No studies have been identified that reported outcomes from the use of DBM alone in this setting. An 89\% (range 62 to 95\%) fusion rate was calculated in these studies. Of the three studies that met the inclusion criteria, two were level III evidence and one was level IV.

### Bone Marrow Aspirate

Autologous bone marrow aspirate (BMA) has been a topic of research for many years. Harvested through a minimally invasive procedure, BMA provides a population of osteoprogenitor cells and critical growth factors that help cell differentiation, leading to bone healing. In vitro studies have demonstrated high colony-forming unit count from BMA obtained from either vertebral body or iliac crest.\textsuperscript{49} Because BMA alone lacks localized structural support, it is often used clinically with an appropriate carrier such as a ceramic.

There is a substantial variability in the processing of BMA, notably with concentrated and nonconcentrated techniques. With a concentrated protocol, bone marrow aspirate is harvested in small volumes and processed through centrifugation, cell separation, and/or retention steps to provide a higher concentration of osteoblast progenitor cells. The proportion of osteogenic progenitor cells in bone marrow has been reported between 1 in 5000 to 100,000 cells. Cell retention techniques can increase this population up to fourfold, theoretically leading to higher performance.

#### Table 1 Fusion Rates for Various Bone Graft Substitutes in Posterolateral Fusion

| Bone Graft Substitute                              | Number of Studies | Number of Patients | Number of Patients Fused | Fusion Rate (\%) | Range (%) |
|---------------------------------------------------|-------------------|--------------------|--------------------------|------------------|-----------|
| Autologous iliac crest bone graft                 | 23                | 1389               | 1103                     | 79               | 40–100    |
| Local autograft alone                             | 8                 | 714                | 637                      | 89               | 65–95     |
| Allograft alone                                    | 4                 | 269                | 141                      | 52               | 0–92      |
| Bone marrow aspirate (concentrated)               | 2                 | 40                 | 34                       | 85               | 78–91     |
| Bone morphogenetic protein-2                      | 3                 | 213                | 201                      | 94               | 90–100    |
| Ceramics\textsuperscript{4}                       | 16                | 697                | 603                      | 87               | 5–100     |
| Demineralized bone matrices\textsuperscript{1}    | 3                 | 192                | 171                      | 89               | 63–97     |
| Autologous growth factors\textsuperscript{1}      | 4                 | 209                | 154                      | 74               | 54–100    |

\textsuperscript{4}Only as extender.
| Authors | Level of Evidence |
|---------|------------------|
| **Allograft** | |
| Impact of instrumentation in lumbar spinal fusion in elderly patients | Anderson T, Christensen FB, Niedermann B, Helmig P, Hoy K, Hansen ES, Bunger C | III |
| Prospective comparison of autograft versus allograft for adult posterolateral spine fusion: differences among freeze-dried, frozen, and mixed grafts | An HS, Lynch K, Toth J | II |
| A prospective analysis of autograft versus allograft in posterolateral lumbar fusion in the same patient | Jorgenson SS, Lowe TG, Franco J, Sabin J | II |
| Use of cryopreserved bone in spinal surgery | Nasca RJ, Whelchel JD | III |
| **BMA (concentrated)** | |
| The clinical use of enriched bone marrow stem cells combined with porous β-tricalcium phosphate in posterior spinal fusion | Gan Y, Dai K, Zhang P, Tang T, Zhu Z, Lu J | IV |
| Bone morphogenetic protein-2 and bone marrow aspirate with allograft as alternatives to autograft in instrumented revision posterolateral lumbar spinal fusion | Taghavi CE, Lee KB, Keorochana G, Tzeng ST, Yoo JH, Wang JC | III |
| rhBMP-2 (INFUSE™) | |
| Posterolateral lumbar spine fusion with infuse bone graft | Glassman SD, Carreon L, Djurasovic M, Campbell MJ, Puno RM, Johnson JR, Dimar JR | III |
| Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation | Dawson E, Bae HW, Burkus K, Stambough JL, Glassman SD | I |
| Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans | Boden SD, Kang J, Sandhu H, Heller JG | I |
| **Ceramic** | |
| Correlative radiological, self-assessment, and clinical analysis of evolution in instrumented dorsal and lateral fusion for degenerative lumbar spine disease: autograft versus coralline hydroxyapatite | Korovessis P, Koureas G, Zacharatos S, Papazisis Z, Lambiris E | I |
| Beta tricalcium phosphate: observation of use in 100 posterolateral lumbar instrumented fusions | Epstein NE | IV |
| Coraline hydroxyapatite and laminectomy-derived bone as an adjuvant graft material for lumbar posterolateral fusion | Hsu CJ, Chou WY, Teng HP, Change WN, Chou YJ | III |
| Efficacy of silicate-substituted calcium phosphate ceramic in posterolateral instrumented lumbar fusion | Jenis LG, Banco RJ | IV |
| Evaluation of autologous platelet concentrate for intertransverse lumbar fusion | Acebal-Cortina G, Suarez-Suarez MA, García-Menendez C, Moro-Barrero L, Iglesias-Colao R, Torres-Perez A | II |
| Single-level instrumented posterolateral fusion of lumbar spine with β-tricalcium phosphate versus autograft | Dai Li, Jiang LS | I |
| The fusion rate of calcium sulfate with local autograft bone compared with autologous iliac bone graft for instrumented short-segment spinal fusion | Chen WJ, Tsai TT, Chen LH, Niu CC, Lai PL, Fu TS, McCarthy K | II |
| Authors                                                                 | Level of Evidence |
|------------------------------------------------------------------------|-------------------|
| Moro-Barrero L, Acebal-Cortina G, Suarez-Suarex M, Perez-Redondo J,    | II                |
| Murcia-Mazon A, Lopez-Muniz A                                          |                   |
| Neen D, Noyes D, Shaw M, Gwilym S, Fairlie N, Birch N                 | IV                |
| Epstein NE                                                             | IV                |
| Chang CH, Lin MZ, Chen YJ, Hsu HC, Chen HT                             | III               |
| Chen CL, Liu CL, Sun SS, Han PY, Lee CS, Lo WH                         | IV                |
| Kanayama M, Hashimoto T, Shigenobu K, Yamane S, Bauer TW, Togawa D    | I                 |
| Niu CC, Tsai TT, Fu TS, Lai PL, Chen LH, Chen WJ                       | II                |
| Tsai CH, Hsu HC, Chen YJ, Lin MJ, Chen HT                              | I                 |
| Acharya NK, Kumar RJ, Varma HK, Menon VK                               | II                |
| Vaccaro AR, Stubbs HA, Block JE                                        | II                |
| Epstein NE, Epstein JA                                                 | IV                |
| Schizas C, Triantafyllopoulos D, Kosmopoulos V, Tzinieris N, Stafylas K| II                |
| Senqupta DK, Truumees E, Patel CK, Kazmierczak C, Hughes B, Elders G,  | III               |
| Herkowitz HN                                                           |                   |
| Moro-Barrero L, Acebal-Cortina G, Suarez-Suarex M, Perez-Redondo J,   | II                |
| Murcia-Mazon A, Lopez-Muniz A                                          |                   |
| Ohtori S, Suzuki M, Koshi T, Takaso M, Yamashita M, Yamauchi K,       | I                 |
| Inoue G, Suzuki M, Orita S, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K,|                   |
| Nakamura J, Aoki Y, Ishikawa T, Arai G, Miyagi M, Kamoda H, Toyone T,  |                   |
| Takahashi K                                                            |                   |
| Inage K, Ohtori S, Koshi T, Suzuki M, Takaso M, Yamashita M, Yamauchi K, Inoue G, Suzuki M, Orita S, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Nakamura J, Aoki Y, Ishikawa T, Arai G, Miyagi M, Kamoda H, Toyone T, Takahashi K | IV |
Table 2 (Continued)

| Procedure                                                                 | Authors                                                                 | Level of Evidence |
|---------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------|
| In situ local autograft for instrumented lower lumbar or lumbosacral posterolateral fusion | Lee SC, Chen JF, Wu CT, Lee ST                                           | IV                |
| Posteriorlateral fusion using laminectomy bone chips in the treatment of lumbar spondylolisthesis | Kho VK, Chen WC                                                         | IV                |
| Uni- and bilateral instrumented posterolateral fusion of the lumbar spine with local bone grafting: a prospective study with a 2-year follow-up | Ohtori S, Koshi T, Suzuki M, Takaso M, Yamashita M, Yamauchi K, Inoue G, Orita S, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Nakamura J, Ishikawa T, Arai G, Miyagi M, Kamoda H, Suzuki M, Furuya T, Toyone T, Takahasi K | IV                |
| Hybrid grafting using bone marrow aspirate combined with porous B-tricalcium phosphate and trephine bone for lumbar posterolateral spinal fusion | Yamada T, Yoshi T, Sotome S, Tuasa M, Kato T, Arai Y, Kawabata S, Tomizawa S, Sakaki K, Hirai T, Shinomiya K, Okawa A | II                |

Autologous growth factor

| Procedure                                                                 | Authors                                                                 |
|---------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Evaluation of autologous platelet concentrate for intertransverse lumbar fusion | Acebal-Cortina G, Suarez-Suarez MA, Garcia-Menendez C, Moro-Barrero L, Iglesias-Colao R, Torres-Perez A | II                |
| Platelet gel fails to increase fusion rates in instrumented posterolateral fusions | Carreron LY, Glassman SD, Anekstein Y, Puno RM                           | III               |
| Use of growth factors-enriched platelet glue in spinal fusion and its efficacy | Tsai CH, Hsu HC, Chen YJ, Lin MJ, Chen HT                                  | I                 |
| Efficacy of autologous growth factors in lumbar intertransverse fusions | Weiner BK, Walker M                                                      | IV                |

BMA, bone marrow aspirate; rhBMP-2, recombinant bone morphogenetic protein-2.

Two studies utilizing a concentrated BMA protocol enrolled 40 patients who underwent a posterolateral lumbar spine fusion. A ceramic carrier (tricalcium phosphate) was used in 22 patients and allograft in 18 patients. An 85% fusion rate was achieved (range 78 to 91%).

Ceramics

Ceramic carriers are derived from a process called “sintering,” which uses high temperatures to extract individual crystals that fused together at crystal grain boundaries. These products are composed of collagen, tricalcium phosphate, calcium sulfate, and/or hydroxyapatite, which are all synthetically based. Because each of these components has different binding, biodegradability, and adhesion characteristics, there is variability seen among carriers depending on composition. Although harboring no osteoinductivity, these carriers can provide an osteoconductive matrix with improved biomechanical properties compared with other conventional carriers.

In eight studies utilizing ceramics as a bone graft extender in our review, a fusion rate of 85% was observed (range 5 to 100%). In each of the studies reporting the use of ceramics in posterolateral lumbar fusion, an osteoinductive autologous source of cells was used (local autograft and/or BMA).

Bone Morphogenetic Protein

First described by Dr. Marshall Urist in 1965, bone morphogenetic protein-2 received FDA approval for the application in the anterior lumbar spine in 2002. Since then, an estimated 85% of the clinical use of rhBMP-2 has been off-label, often in the posterolateral lumbar spine. The complication rates with the use of rhBMP-2 have been well-publicized; however, it appears that the incidence of untoward effects is less when used in the posterolateral lumbar compared with other areas.

Bone morphogenetic protein activates the bone healing cascade through the Smad complex protein pathway that leads to the activation of important genes such as runx and osterix. Although there are over 20 proteins identified in the BMP family, BMP-2 has been the most widely studied in the induction of bone formation. BMPs have other important roles in differentiation of a wide variety of cells such as chondrogenic, cardiac, neural, and epidermal induction. The exact mechanisms behind the reported complications has not been elucidated; however, investigators have postulated angiogenic, inflammatory, and osteoclastic pathways.

Three studies were identified utilizing the INFUSE™ product containing rhBMP-2 and an absorbable collagen sponge in a posterolateral lumbar spine fusion. A fusion rate of 94% was achieved in this group.

Platelet Concentrates

Platelet concentrate products are derived from platelet-rich plasma (PRP), which involves concentrating whole blood through a centrifugation process. The result is a pellet rich in growth factors such as platelet-derived growth factor, transforming growth factor-β, vascular endothelial growth factor, insulin growth factor, and epidermal growth factor.
Furthermore, mesenchymal stem cells are also present, which provide an opportunity for differentiation into primary osteoblasts. However, variability in processing methods, classification systems, and terminology has led to wide inconsistency in the results of its use in many orthopedic conditions, including bone healing. For example, reported platelet concentration counts between different purification systems are drastically different. This variability is increased, considering that the method of platelet counting (manual versus automated) has not been standardized. Finally, it is thought that inhibitory factors, both identified and unknown, are also present in PRP that may modulate the host response after implantation.

Two studies were identified that reported the use of PRP in spine fusion. Surprisingly, a low rate of fusion was observed at 60%. In fact, in these studies, the authors concluded that the addition of PRP inhibited successful lumbar spine fusion. This fusion rate was significantly lower than iliac crest bone graft alone group in one study.

Discussion

Despite the widespread use of bone graft substitutes in posterolateral lumbar spine fusion on a daily basis worldwide, the clinical evidence that helps guide decision making and reduce complication rates is sparse. Even many of the available studies have substantial methodological flaws, including the lack of a control group. Historical data across 3 decades are difficult to compare because of the improvement of instrumentation, variations of surgical technique, and inherent differences in processing methods of products such as that of BMA, DBM, and platelet concentrates. The landscape for the use of these products has and will continue to rapidly change as increased scrutiny is pointed toward the elimination of complications, cost-reduction strategies, and the regulatory climate around bone graft substitutes. Given the number and range of biologics on the market, comparative clinical effectiveness research is important to improve treatments and outcomes for patients electing for spine surgery.

The burden on surgeon education to date has been largely left to the opinions of industry representatives making claims about product safety and efficacy. In addition, the large number of products is not easily addressed by independent research from isolated sources. Finally, the constant addition of 510k-approved and “minimally manipulated human allograft” graft products to the market occurs at a rate that exceeds that of independent research. The field of spine surgery deserves a comprehensive, controlled, multicenter, and independently managed osteobiologics registry that would collect data on patients in a standardized fashion. Utilizing such a tool would allow for the study of many different products in a homogenous patient population with standardized follow-up points. With this prospective study design, the conclusions derived would be much more powerful than a systematic review. An effective method for collecting postmarket data are the registry model. Hendron et al describe the stakeholders and the deficiencies in the current approach to health care technology assessment and in doing so define the role for clinical databases registries in postmarket surveillance and health care technology assessment. Registries are a means of prospectively collecting data that enables continued assessment of effectiveness, especially in regards to new technology and treatments. Similarly, Malchau et al described a stepwise algorithm of introducing new technology, where the final step is administering registry-based studies.

The Osteobiologics Collaborative, an independent study group, will assemble uniquely qualified clinicians and clinician-scientists to address this void through the Resources for Medical Education and Collaboration (RMEC) Osteobiologics Registry. To reach this goal, the following will be implemented:

1. A study group of clinical investigators and researchers to commit to the collection, analysis, and dissemination of data surrounding the application of osteobiologics in spine surgery;
2. Organized meetings to develop, enable, and promote research surrounding the application of osteobiologics in spine surgery;
3. Collection of multicenter data surrounding the application of osteobiologics in spine surgery;
4. Resources and pathways for dissemination of data and evidence to clinicians that effectively communicate safety and efficacy considerations in the application of osteobiologics.

Conclusions

Bone graft substitutes and extenders are utilized daily in spine surgery, yet the evidence surrounding commercially available products that guides surgeon choice is sparse. Independent efforts to study and report comparative results with different spinal biologics are necessary in a cost-conscious, outcomes-driven health care world. A spine fusion registry promoted by The Osteobiologics Collaborative, through the Resources for Medical Education and Collaboration, is one step toward answering important questions to improve the delivery of patient care with spinal disorders.

This effort will aim to improve patient care and outcomes, reduce complications, track cost data, and identify solutions for osteobiologics in spine surgery. For more information, please contact: Caitlyn McCullough, Executive Director, Resources for Medical Education and Collaboration, 1 Mercado Street, Ste 202, Durango, CO 81301 (phone: 970–375–3649; e-mail: Caitlyn@resourcesmec.org).

Funding

Funding was made possible in part (grant #11-278) from the Orthopaedic Research and Education Foundation (OREF). The views expressed in written conference materials, the views expressed by speakers and in publications or written conference materials do not necessarily reflect official policies of OREF.
Disclosures

W. K. Hsu, Consulting: Stryker, Pioneer, Medtronic, Zimmer, Grafys; Research Support: Baxter, Pioneer
M. S. Nickoli, None

J. C. Wang, Royalties: Medtronic, Stryker, Seaspine, Osprey, Aesculap, Biomet, Amedica, Zimmer, Synthes; Stock Ownership: Fziomed; Private Investments: Prometheus Spine, Paradigm Spine, Benevenue, NexGen, K2 Medical, Pioneer, Amedica, Vertiflex, Electrocore, Surgitech, Axiomed; Board of Directors: North American Spine Society, Cervical Spine Research Society, AO Spine/AO Foundation; Scientific Advisory Board: VG Innovations, CoreSpine, Expanding Orthopaedics, Syndicom, Osprey, Amedica, Bone Biologics, Curative Biosciences, PearDiver, Inc., Pioneer, Seaspine

J. R. Lieberman, Research Support: Amgen, Inc., NIH; Advisory Board, Amgen, Inc.

H. S. An, Consulting: Advanced Biologics, Inc., Pioneer, Inc.; Research support: Baxter, Inc.

S. T. Yoon, None

J. A. Youssef, Consultant: NuVasive, Integra; Royalty: NuVasive, Aesculap/B. Braun, Osprey, Amedica; Research Support: DePuy, Stryker, NuVasive, BioSurface Engineering Technologies, Globus Medical, Advanced Technologies in Regenerative Medicine, Axial Biotech, Vertiflex; Stock Options: Amedica, Pioneer, Vertiflex, Benvenue Medical, Inc., Paradigm Spine, Prometheus Surgical Devices, Spinal Ventures

D. S. Brodke, None

C. M. McCullough, None

References

1 Ludwig SC, Kowalski JM, Boden SD. Osteoinductive bone graft substitutes. Eur Spine J 2000;9(1):S119–S125

2 Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011;11:471–491

3 Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol 2008;81:362–378

4 An HS, Lynch K, Toth J. Prospective comparison of autograft vs. allograft for adult posterolateral lumbar spine fusion: differences among freeze-dried, frozen, and mixed grafts. J Spinal Disorders 1995;8:131–135

5 Jorgenson SS, Lowe TG, France J, Sabin J. A prospective analysis of autograft versus allograft in posterolateral lumbar fusion in the same patient. A minimum of 1-year follow-up in 144 patients. Spine 1994;19:2048–2053

6 Andersen T, Christensen FB, Niedermann B, et al. Impact of instrumentation in lumbar spinal fusion in elderly patients: 71 patients followed for 2–7 years. Acta Orthop 2009;80:445–450

7 Nasca RJ, Wheelchel JD. Use of cryopreserved bone in spinal surgery. Spine 1987;12:222–227

8 Gan Y, Dai K, Zhang P, Tang T, Zhu Z, Lu J. The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion. Biomaterials 2008;29:3973–3982

9 Taghavi CE, Lee KB, Keorochana G, Tzeng ST, Yoo JH, Wang JC. Bone morphogenetic protein-2 and bone marrow aspirate with allograft as alternatives to autograft in instrumented revision posterolateral lumbar spinal fusion: a minimum two-year follow-up study. Spine 2010;35:1144–1150

10 Korovessis P, Kouroumas G, Zacharatos S, Papazisis Z, Lambiris E. Correlative radiological, self-assessment and clinical analysis of evolution in instrumented dorsal and lateral fusion for degenerative lumbar spine disease. Autograft versus coraline hydroxyapatite. Eur Spine J 2005;14:630–638

11 Epstein NE. Beta tricalcium phosphate: observation of use in 100 posterolateral lumbar instrumented fusions. Spine J 2009;9:630–638

12 Hsu CJ, Chou WY, Teng HP, Chang WN, Chou YJ. Coraline hydroxyapatite and laminectomy-derived bone as adjuvant graft material for lumbar posterolateral fusion. J Neurosurg Spine 2005;3:271–275

13 Jenis LG, Banco RJ. Efficacy of silicate-substituted calcium phosphate ceramic in posterolateral instrumented lumbar fusion. Spine 2010;35:E1058–E1063

14 Acebal-Cortina G, Suárez-Suárez MA, García-Menéndez C, Moro-Barrero I, Iglésias-Colao R, Torres-Pérez A. Evaluation of autologous platelet concentrate for intertransverse lumbar fusion. Eur Spine J 2011;20(Suppl 3):361–366

15 Dai LY, Jiang LS. Single-level instrumented posterolateral fusion of lumbar spine with beta-tricalcium phosphate versus autograft: a prospective, randomized study with 3-year follow-up. Spine 2008;33:1299–1304

16 Chen WJ, Tsai TT, Chen LH, et al. The fusion rate of calcium sulfate with local autograft bone compared with autologous iliac bone graft for instrumented short-segment spinal fusion. Spine 2005;30:2293–2297

17 Moro-Barrero L, Acebal-Cortina G, Suárez-Suárez M, Pérez-Redondo J, Murcia-Mazón A, López-Muñiz A. Radiographic analysis of fusion mass using fresh autologous bone marrow with ceramic composites as an alternative to autologous bone graft. J Spinal Disord Tech 2007;20:409–415

18 Neen D, Noyes D, Shaw M, Gwilym S, Fairlie N, Birch N. Heals and bone marrow aspirate used for lumbar spine fusion: a case controlled study comparing heals with autograft. Spine 2006;31:E636–E640

19 Epstein NE. A preliminary study of the efficacy of Beta Tricalcium Phosphate as a bone expander for instrumented posterolateral lumbar fusions. J Spinal Disord Tech 2006;19:424–429

20 Chang CH, Lin MZ, Chen YJ, Hsu HC, Chen HT. Local autogenous bone mixed with bone expander: an optimal option of bone graft in single-stage posterolateral lumbar fusion. Spine 2008;33:1299–1300

21 Chen CL, Liu CL, Sun SS, Han FY, Lee CS, Lo WH. Posterolateral lumbar spinal fusion with autogenous bone chips from lamincetomy extended with OsteoSet. J Chin Med Assoc 2006;69:581–584

22 Kanayama M, Hashimoto T, Shigenobu K, Yamane S, Bauer TW, Togawa D. A prospective randomized study of posterolateral lumbar fusion using osteogenic protein-1 (OP-1) versus local autograft with ceramic bone substitute: emphasis of surgical exploration and histologic assessment. Spine 2006;31:1067–1074

23 Niu CC, Tsai TT, Fu TS, Lai PL, Chen LH, Chen WJ. A comparison of posterolateral lumbar fusion comparing autograft, autogenous lamincetomy bone with bone marrow aspirate, and calcium sulphate with bone marrow aspirate: a prospective randomized study. Spine 2009;34:2715–2719

24 Acharya NK, Kumar RJ, Varma HK, Menon VK. Hydroxyapatite-bioactive glass ceramic composite as stand-alone graft substitute for posterolateral fusion of lumbar spine: a prospective, matched, and controlled study. J Spinal Disord Tech 2008;21:106–111

25 Tsai CH, Hsu HC, Chen YJ, Lin MJ, Chen HT. Using the growth factors-enriched platelet glue in spinal fusion and its efficiency. J Spinal Disord Tech 2009;20:246–250
Vaccaro AR, Stubbs HA, Block JE. Demineralized bone matrix composite grafting for posterolateral spinal fusion. Orthopedics 2007;30:567–570

Epstein NE, Epstein JA. SF-36 outcomes and fusion rates after multilevel laminectomies and 1 and 2-level instrumented posterolateral fusions using lamina autograft and demineralized bone matrix. J Spinal Disord Tech 2007;20:139–145

Schizas C, Triaftafyllopoulos D, Kosmopoulos V, Tziniaris N, Stafylas K. Posterolateral lumbar spine fusion using a novel demineralized bone matrix: a controlled case pilot study. Arch Orthop Trauma Surg 2008;128:621–625

Sengupta DK, Truumees E, Patel CK, et al. Outcome of local bone versus autogenous iliac crest bone graft in the instrumented posterolateral fusion of the lumbar spine. Spine 2006;31:985–991

Ohtori S, Koshi T, Suzuki M, et al. Uni- and bilateral instrumented posterolateral fusion of the lumbar spine with local bone grafting: a prospective study with a 2-year follow-up. Spine 2011;36:E1744–E1748

Inage K, Ohtori S, Koshi T, et al. One, two-, and three-level instrumented posterolateral fusion of the lumbar spine with a local bone graft: a prospective study with a 2-year follow-up. Spine 2011;36:1392–1396

Lee SC, Chen JF, Wu CT, Lee ST. In situ local autograft for instrumented lower lumbar or lumbosacral posterolateral fusion. J Clin Neurosci 2009;16:37–43

Kho VK, Chen WC. Posterolateral fusion using laminectomy bone chips in the treatment of lumbar spondylolisthesis. Int Orthop 2008;32:115–119

Yamada T, Yoshii T, Sotome S, et al. Hybrid grafting using bone marrow aspirate combined with porous β-tricalcium phosphate and trephine bone for lumbar posterolateral spinal fusion: a prospective, comparative study versus local bone grafting. Spine 2012;37:E174–E179

Glassman SD, Carreon L, Djurasovic M, et al. Posterolateral lumbar spine fusion with INFUSE bone graft. Spine J 2007;7:44–49

Dawson E, Bae HW, Burkus JK, Stambough JL, Glassman SD. Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation. A prospective randomized trial. J Bone Joint Surg Am 2009;91:1604–1613

Boden SD, Kang J, Sandhu H, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral spinal fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 2002;27:2662–2673

Weiner BK, Walker M. Efficacy of autologous growth factors in lumbar intertransverse fusions. Spine 2003;28:1968–1970; discussion 1971

Carreon LY, Glassman SD, Anekiestyn Y, Puno RM. Platelet gel (AGF) fails to increase fusion rates in instrumented posterolateral fusions. Spine 2005;30:E243–E246; discussion E247

Miura Y, Imagama S, Yoda M, Mitsaguchi H, Kachi H. Is local bone viable as a source of bone graft in posterior interbody fusion? Spine 2003;28:2386–2389

Lee JH, Jeon DW, Lee SJ, Chang BS, Lee CK. Fusion rates and subsidence of morselized local bone grafted in titanium cages in posterior lumbar interbody fusion using quantitative three-dimensional computed tomography scans. Spine 2010;35:1460–1465

Defino HL, da Silva Herrero CF, Crippa GE, Bellesini LS, Beloti MM, Rosa AL. In vitro proliferation and osteoblastic phenotype expression of cells derived from human vertebral lamina and iliac crest. Spine 2009;34:1549–1553

Gazdag AR, Lane JM, Glaser D, Forster RA. Alternatives to autogenous bone graft: efficacy and indications. J Am Acad Orthop Surg 1995;3:1–8

Finkemeier CG. Bone-grafting and bone-graft substitutes. J Bone Joint Surg Am 2002;84-A:454–464

Lee KJ, Roper JC, Wang JC. Demineralized bone matrix and spinal arthrodesis. Spine J 2005;5(S6, Suppl):217S–223S

Peterson B, Whang PG, Iglesias R, Wang JC, Lieberman JR. Osteoinductivity of commercially available demineralized bone matrix. Preparations in a spine fusion model. J Bone Joint Surg Am 2004;86-A:2243–2250

Bae HW, Zhao L, Kim LE, Wong P, Delamarter RB, Dawson EG. Intervertebral and intravariability of bone morphogenetic proteins in commercially available demineralized bone matrix products. Spine (Phila Pa 1976) 2006;31:1299–1306; discussion 1307–1308

Bae H, Zhao L, Zhu D, Kim LE, Wang JC, Delamarter RB. Variability across ten production lots of a single demineralized bone matrix product. J Bone Joint Surg Am 2010;92:427–435

McLain RF, Fleming JE, Boehm CA, Muschler GF. Aspiration of osteoprogenitor cells for augmenting spinal fusion: comparison of progenitor cell concentrations from the vertebral body and iliac crest. J Bone Joint Surg Am 2005;87:2655–2661

Urish MR. Bone: formation by autoinduction. Science 1965;150:839–899

Consugar MB, Wong WC, Lundquist PA, et al; CRISP Consortium. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TKSC2 contiguous gene syndrome. Kidney Int 2008;74:1468–1479

Mroz TE, Wang JC, Hashimoto R, Norvell DC. Complications related to osteobiologics use in spine surgery: a systematic review. Spine (Phila Pa 1976) 2010;35(9, Suppl):S86–S104

Cahill KS, Chi JH, Day A, Claus EB. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 2009;302:38–46

Vaidya R. Transforaminal interbody fusion and the “off label” use of recombinant human bone morphogenetic protein-2. Spine J 2009;9:667–669

Vaidya R, Carp J, Sethi A, Bartol S, Craig J, Les CM. Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2. Eur Spine J 2007;16:1257–1265

Vaidya R, Sethi A, Bartol S, Jacobson M, Coe C, Craig JG. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions. J Spinal Disord Tech 2008;21:557–562

Vaidya R, Weir R, Sethi A, Meisterling S, Hakeos W, Wybo CD. Interbody fusion with allograft and rhBMP-2 leads to consistent fusion but early subsidence. J Bone Joint Surg Br 2007;89:342–345

McClellan JW, Mulconrey DS, Forbes RJ, Fuller N. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech 2006;19:483–486

Muchow RD, Hsu WK, Anderson PA. Histopathologic inflammatory response induced by recombinant bone morphogenetic protein-2 causing radiculopathy after transforaminal lumbar interbody fusion. Spine J 2010;10:e1–e6

Wong DA, Kumar A, Satana S, Ghaselli G, Wong K. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J 2008;8:1011–1018

Vaccaro AR, Patel T, Fischgrund J, et al. A pilot study evaluating the safety and efficacy of OP-1 Putty (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis for degenerative spondylolisthesis. Spine 2004;29:1885–1892

Cheng H, Jiang W, Phillips FM, et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 2003;85-A:1544–1552
Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004;22:233–241

Lee KB, Taghavi CE, Song KJ, et al. Inflammatory characteristics of rhBMP-2 in vitro and in an in vivo rodent model. Spine (Phila Pa 1976) 2011;36:E149–E154

Deckers MM, van Bezooijen RL, van der Horst G, et al. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 2002;143:1545–1553

Otsuka E, Notoya M, Hagiwara H. Treatment of myoblastic C2C12 cells with BMP-2 stimulates vitamin D-induced formation of osteoclasts. Calcif Tissue Int 2003;73:72–77

Castillo TN, Pouliot MA, Kim HJ, Dragoo JL. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med 2011;39:266–271

Mazzucco L, Balbo V, Cattana E, Guascino R, Borzini P. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateltex and one manual procedure. Vox Sang 2009;97:110–118

Herndon JH, Hwang R, Bozic KJ. Healthcare technology and technology assessment. Eur Spine J 2007;16:1293–1302

Malchau H. Introducing new technology: a stepwise algorithm. Spine (Phila Pa 1976) 2000;25:285